NCT00151541已完成3 期
A Phase 3, Randomized, Double-blind, Multi-dose Study to Evaluate the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG 5%) When Co-administered With Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4% in the Treatment of Acne Vulgaris.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 301
- 主要终点
- The primary efficacy endpoint will be mean percent reduction in inflammatory lesion counts.
研究概览
简要总结
The purpose of this study is to compare the safety and efficacy of 5% Dapsone Topical Gel, (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. The second objective of the study is to determine dapsone exposure after co-administration of DTG 5% with vehicle control, adapalene or benzoyl peroxide gel.
详细描述
This is a 3 arm, 12-week, randomized, double-blind, multicenter study comparing safety and efficacy of DTG 5% twice daily plus vehicle control once daily vs. DTG 5% twice daily plus adapalene gel 0.1% once daily vs. DTG 5% twice daily plus 4% benzoyl peroxide gel once daily in subjects with acne vulgaris. Approximately 300 male and female subjects, 12 years of age and older, with acne vulgaris and > 20 inflammatory lesions (papules and/or pustules) and > 20 non-inflammatory lesions (comedones) above the mandibular line at Baseline will be enrolled. Follow-up visits will occur at Week 2, 4, 8 and 12. Global Acne Assessments, Lesion Counts and Local Adverse Reaction Assessments will be conducted at each visit. A physical exam will be done at Baseline and Week 12. Plasma Dapsone Level samples will be drawn at Baseline, Week 2 and Week 12/ET for dapsone plasma level assessments. Adverse events and concomitant medications will be assessed throughout the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Study subjects will be considered for participation based upon medical history and findings from the pre-study interview and examination. They will be enrolled according to the following conditions:
- •Each subject or parent/guardian will read and sign the informed assent and/or consent form as required by IRB regulations. If a subject should require someone to read and/or interpret any or all of the informed consent, a statement of this fact will be documented. If a subject is unable to read or if a legally acceptable representative is unable to read, an impartial witness should be present during the entire informed consent discussion to ensure accurate representation of the informed consent document is given verbally. If a subject does not understand English, a validated translated informed consent agreement will be provided. If the subject is a minor, the signature of their parent or guardian will be required per Institutional Review Board regulations.
- •Male and female subjects, 12 years of age and older.
- •A female subject of childbearing potential must not be pregnant or nursing. All female subjects must be practicing an effective method of birth control as determined by the Investigator. Any female who is not sexually active must agree to begin using an effective method of birth control, excluding hormonal birth control, if she becomes sexually active during the study.
- •A female subject using hormonal birth control must have been on a stable dose for 3 months prior to Baseline.
- •Note: A surgically sterilized partner is not an acceptable method of birth control.
- •A urine pregnancy test will be required of all female subjects, 60 years of age and younger prior to treatment. If the subject can provide documentation of surgical sterilization, at the baseline visit, a pregnancy test is not required.
- •Negative test results must be obtained prior to randomization.
- •Subjects must be in good physical and mental health.
- •The subject must be willing to avoid swimming and bathing for 2 hours following test article application. Additionally, the subject must be willing to avoid moisturizers, sunscreens and cosmetics for 1 hour following test article application.
- •The subject must score > 2 on the Global Acne Assessment Score at Baseline (Appendix D).
- •Subjects must have a clear diagnosis of acne vulgaris of the face, and have a minimum of 20 inflammatory lesions (pustules and papules) and 20 non-inflammatory lesions (comedones) above the mandibular line at Baseline. If, in the judgment of the Investigator, the subject's acne should be treated with a systemic acne medication, they should not be enrolled in the study.
- •Subjects must be willing to undergo blood draws throughout the study.
- •The subject must be willing and able to comply with the requirements of the protocol
排除标准
- •MEDICATIONS EXCLUDED IN THE ADMISSION CRITERIA WILL NOT BE PERMITTED DURING THE STUDY.
- •Subjects who meet any of the following criteria will be excluded from study entry:
- •Subjects using systemic immunosuppressive medications within 28 days prior to Baseline and throughout the study. Intranasal and/or inhaled corticosteriods are acceptable throughout the study if at a stable and standard dose, as labeled within the Package Insert.
- •Subjects who are using topical agents for acne (including and not limited to benzoyl peroxide, antibiotics, topical vitamin A derivates such as retinol or retinoids, medicated cosmetics, cleansers) within 14 days prior to Baseline and throughout the study. This includes over the counter medications and cleansers that contain acne treatment ingredients, e.g. benzoyl peroxide, salicylic acid.
- •Subjects who have received light therapies (ultraviolet B, tanning bed, lasers, photodynamic treatment), systemic medications, or skin treatments known to affect acne or inflammatory responses within the 28 days prior to Baseline and throughout the study. This includes but is not limited to: antibiotics, large doses (>50,000 U/day) of vitamin A, hormones (excluding those used for birth control), spironolactone, aldactone, aldactizide, cyproterone acetate, NSAIDS and chemical exfoliative treatments (alpha-hydroxy acid or "fruit-wash," "lunchtime" or phenol peels) or physical peels (laser, "dry ice" peels). Short-term treatment with antibiotics and NSAIDS during the study for non-acne related conditions is acceptable provided that exposure is limited to 14 days per course for antibiotics and 7 days per month for NSAIDS.
- •Subjects who have received isotretinoin (Accutane) within the three months prior to Baseline and throughout the study.
- •Subjects that have participated in any previous QLT USA, Inc. (formerly Atrix Laboratories, Inc.) dapsone topical gel studies.
- •Subjects who have any medical condition which, in the Investigator's judgment, makes the subject an inappropriate study candidate.
- •Subjects who have any condition that would hinder accurate facial acne evaluations including excessive facial hair (beard), excessive scarring, sunburn or other disfigurement.
- •Subjects with severe cystic acne or acne conglobata.
- •Subjects with any active or developing nodules above the mandibular line at Baseline.
- •Subjects with a known allergy or hypersensitivity to dapsone, adapalene, benzoyl peroxide, or any component of the study products.
- •Subjects taking another investigational test article within the 30 days prior to Baseline or throughout the study.
- •Female subjects having started a new, or having changed their current hormonal contraceptive or hormone replacement therapy within three months prior to Baseline. Subjects receiving Depo Provera® injections in preceding 4 months are excluded from the study.
结局指标
主要结局
The primary efficacy endpoint will be mean percent reduction in inflammatory lesion counts.
次要结局
- Additional efficacy endpoints will be the mean percent reduction from Baseline in non-inflammatory and total lesion counts, as well as the proportion of subjects who achieve success (none/minimal) on a 5-point Global Acne Assessment Score.
- Safety endpoints will include treatment-emergent and treatment related adverse events. An additional safety endpoint will be the local adverse reaction assessment.
研究者
相似试验
进行中（未招募）
不适用
A phase II trial assessing dapsone topical gel in the prevention and treatment of erlotinib associated rashThe study population are patients with non-small cell lung carcinoma eligible for treatment with erlotinib (TarcevaTM). A significant number of these patients develop acne-like rash as a side effect of erlotinib.EUCTR2006-000390-30-FIHelsinki University Central Hospital, Skin and Allergy Hospital30
已完成
2 期
Dapson in acne vulgarisIRCT2017072035195N1Rasht University of Medical Sciences60
终止
4 期
Use of Dapsone Gel, 5% for Treating Dermatitis HerpetiformisDermatitis HerpetiformisNCT01115244Vanderbilt University Medical Center1
已完成
3 期
Trial of Dapsone 5.0% Gel in the Treatment of Acne VulgarisAcne VulgarisNCT02865005Seegpharm S.A.2,361
已完成
4 期
Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne VulgarisAcne VulgarisNCT00834210Allergan171